Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset

Nodler, J.L.; Moolamalla, Surjit R; Ledger, Elizabeth; Nuwayhid, B.; Mulla, Zuber D.

doi:10.1186/1471-2393-9-11

Cited by 64 publications

(42 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For decades, women particularly with SLE were advised against pregnancy given high rates of observed poor outcomes, concern for disease flare and lack of evidence for safe treatment options. Indeed, women with SLE/APS especially have higher rates of preeclampsia, intrauterine growth restriction (IUGR), and prematurity [2–4]. However, with advances in disease management, pregnancy outcomes in these populations have improved, and increasingly more women with CTDs are choosing to attempt pregnancies [5].…”

mentioning

confidence: 99%

Pregnancy and autoimmune connective tissue diseases

Marder

Littlejohn

Somers

2016

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

The autoimmune connective tissue diseases predominantly affect women and often occur during the reproductive years. Thus, specialized issues in pregnancy planning and management are commonly encountered in this patient population. This chapter provides a current overview of pregnancy as a risk factor for onset of autoimmune disease, considerations related to the course of pregnancy in several autoimmune connective tissue diseases, and disease management and medication issues before and during pregnancy and the postpartum period. A major theme that has emerged across these inflammatory diseases is that active maternal disease during pregnancy is associated with adverse pregnancy outcomes, and that maternal and fetal health can be optimized when conception is planned during times of inactive disease and through maintaining treatment regimens compatible with pregnancy.

show abstract

mentioning

confidence: 99%

Pregnancy and autoimmune connective tissue diseases

Marder

Littlejohn

Somers

2016

Best Practice & Research Clinical Rheumatology

View full text Add to dashboard Cite

show abstract

“…PE and intrauterine growth restriction (IUGR) -associated with impaired placentation -are obstetric complications frequently observed in APS (9)(10)(11)(12). Both conditions are major causes of maternal and fetal morbidity worldwide, with uncertain prevention and management (13,14).…”

Section: Introductionmentioning

confidence: 99%

Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy

Lefkou¹,

Mamopoulos²,

Dagklis³

et al. 2016

Journal of Clinical Investigation

164

143

View full text Add to dashboard Cite

“…HELLP syndrome is defined as an endothelium-based disorder [61,62]. The increased prevalence of HELLP syndrome suggested by Ruffatti et al [69] 2006 Previous thromboembolism and/or triple antiphospholipid antibody positivity Sailer et al [39] 2006 Multiple antiphospholipid antibody positivity Danowski et al [45] 2009 Association with SLE or other SAD Nodler et al [53] 2009 High antiphospholipid antibody titres Ruffatti et al [70] 2009 Antiphospholipid antibody category I (Sydney criteria) or triple antiphospholipid antibody positivity…”

Section: Authors (Reference) Year Clinical Reports Treatment Protocolmentioning

confidence: 98%

“…More specific obstetrical manifestations include severe preeclampsia, which generally affects 2-8 % of pregnancies [52]. A cross-sectional study conducted in Florida on 141,286 women who delivered in 2001 showed that women with high antiphospholipid antibody titres had an increased risk of preeclampsia or eclampsia (adjusted odds ratio [AOR] = 2.93), placenta insufficiency (AOR = 4.58) and prolonged length of stay at hospital (>3 days, AOR = 3.93) [53]. Moreover, APS patients with history of cerebral ischemic events are at increased risk of preeclampsia (34.8 %), especially those positive for multiple antiphospholipid antibody test, and new cerebral ischemia can occur if preeclampsia develops (OR = 7.0) [42].…”

Section: Authors (Reference) Year Clinical Reports Treatment Protocolmentioning

confidence: 99%

Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review

Ruffatti

Hoxha

Favarò

et al. 2016

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Most investigators currently advocate prophylactic-dose heparin plus low-dose aspirin as the preferred treatment of otherwise healthy women with obstetric antiphospholipid syndrome, whilst women with a history of vascular thrombosis alone or associated with pregnancy morbidity are usually treated with therapeutic heparin doses in association with low-dose aspirin in an attempt to prevent both thrombosis and pregnancy morbidity. However, the protocols outlined above fail in about 20 % of pregnant women with antiphospholipid syndrome. Identifying risk factors associated with pregnancy failure when conventional therapies are utilized is an important step in establishing guidelines to manage these high-risk patients. Some clinical and laboratory risk factors have been found to be related to maternal-foetal complications in pregnant women on conventional therapy. However, the most efficacious treatments to administer to high-risk antiphospholipid syndrome women in addition to conventional therapy in order to avoid pregnancy complications are as yet unestablished. This is a comprehensive review on this topic and an invitation to participate in a multicentre study in order to identify the best additional treatments to be used in this subset of antiphospholipid syndrome patients.

show abstract

Elevated antiphospholipid antibody titers and adverse pregnancy outcomes: analysis of a population-based hospital dataset

Cited by 64 publications

References 15 publications

Pregnancy and autoimmune connective tissue diseases

Pregnancy and autoimmune connective tissue diseases

Pravastatin improves pregnancy outcomes in obstetric antiphospholipid syndrome refractory to antithrombotic therapy

Additional Treatments for High-Risk Obstetric Antiphospholipid Syndrome: a Comprehensive Review

Contact Info

Product

Resources

About